ATE544866T1 - Adamts13-haltige zusammensetzungen mit thrombolytischer wirkung - Google Patents

Adamts13-haltige zusammensetzungen mit thrombolytischer wirkung

Info

Publication number
ATE544866T1
ATE544866T1 AT06754405T AT06754405T ATE544866T1 AT E544866 T1 ATE544866 T1 AT E544866T1 AT 06754405 T AT06754405 T AT 06754405T AT 06754405 T AT06754405 T AT 06754405T AT E544866 T1 ATE544866 T1 AT E544866T1
Authority
AT
Austria
Prior art keywords
thrombus
compositions containing
adamts13
thrombolytic action
containing adamts13
Prior art date
Application number
AT06754405T
Other languages
English (en)
Inventor
Denisa Wagner
Anil Chauhan
Friedrich Scheiflinger
Barbara Plaimauer
Original Assignee
Baxter Int
Baxter Healthcare Sa
Cbr Inst For Biomedical Res
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Baxter Int, Baxter Healthcare Sa, Cbr Inst For Biomedical Res filed Critical Baxter Int
Application granted granted Critical
Publication of ATE544866T1 publication Critical patent/ATE544866T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6489—Metalloendopeptidases (3.4.24)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
AT06754405T 2005-06-17 2006-06-16 Adamts13-haltige zusammensetzungen mit thrombolytischer wirkung ATE544866T1 (de)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US69192705P 2005-06-17 2005-06-17
US72932305P 2005-10-21 2005-10-21
US77126506P 2006-02-07 2006-02-07
PCT/EP2006/005800 WO2006133955A1 (en) 2005-06-17 2006-06-16 Adamts13-comprising compositions having thrombolytic activity

Publications (1)

Publication Number Publication Date
ATE544866T1 true ATE544866T1 (de) 2012-02-15

Family

ID=36956096

Family Applications (1)

Application Number Title Priority Date Filing Date
AT06754405T ATE544866T1 (de) 2005-06-17 2006-06-16 Adamts13-haltige zusammensetzungen mit thrombolytischer wirkung

Country Status (9)

Country Link
US (4) US20070015703A1 (de)
EP (1) EP1902141B1 (de)
AT (1) ATE544866T1 (de)
AU (1) AU2006257073B2 (de)
CA (1) CA2606351C (de)
DK (1) DK1902141T3 (de)
ES (1) ES2382104T3 (de)
PL (1) PL1902141T3 (de)
WO (1) WO2006133955A1 (de)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6969601B2 (en) 1997-04-03 2005-11-29 Jensenius Jens Chr MASP-2, a complement-fixing enzyme, and uses for it
US8840893B2 (en) 2004-06-10 2014-09-23 Omeros Corporation Methods for treating conditions associated with MASP-2 dependent complement activation
US7919094B2 (en) * 2004-06-10 2011-04-05 Omeros Corporation Methods for treating conditions associated with MASP-2 dependent complement activation
ATE544866T1 (de) 2005-06-17 2012-02-15 Baxter Int Adamts13-haltige zusammensetzungen mit thrombolytischer wirkung
FR2918375B1 (fr) * 2007-07-05 2009-10-16 Lab Francais Du Fractionnement Utilisation d'un support de chromatographie pour reduire la quantite d'adamts13 dans une solution derivee du plasma
AU2009246603B8 (en) * 2008-05-12 2015-08-13 Children's Medical Center Corporation von Willebrand Factor (VWF) inhibitors for treatment or prevention of infarction
CA2741634A1 (en) * 2008-10-27 2010-06-03 Baxter International Inc. Models of thrombotic thrombocytopenic purpura and methods of use thereof
ES2685503T3 (es) * 2008-12-05 2018-10-09 Baxalta GmbH Métodos de medida de la división in vivo de Factor von Willebrand mediada por ADAMTS13 y utilización de los mismos
JP5411582B2 (ja) * 2009-06-02 2014-02-12 一般財団法人化学及血清療法研究所 Ａｄａｍｔｓ１３による細胞移植増強補助剤
US8580554B2 (en) 2009-07-31 2013-11-12 Baxter International Inc. Method of producing a polypeptide or virus of interest in a continuous cell culture
US8945895B2 (en) 2009-07-31 2015-02-03 Baxter International Inc. Methods of purifying recombinant ADAMTS13 and other proteins and compositions thereof
PL4218797T3 (pl) 2009-09-21 2025-02-10 Takeda Pharmaceutical Company Limited Stabilizowane płynne i liofilizowane preparaty adamts13
DK2488203T3 (en) * 2009-10-16 2017-03-13 Omeros Corp METHODS OF TREATING DISSEMINATED INTRAVASCULAR COAGULATION BY INHIBITION OF MASP-2 DEPENDENT COMPLEMENT ACTIVATION
US9644035B2 (en) 2011-04-08 2017-05-09 Omeros Corporation Methods for treating conditions associated with MASP-2 dependent complement activation
BR112013025917A2 (pt) 2011-04-08 2016-12-20 Omeros Corp uso de um anticorpo masp-2 ou fragmento do mesmo que inibe ativação de complemento dependente de masp-2
AU2013203062C1 (en) * 2013-03-15 2018-06-28 Takeda Pharmaceutical Company Limited Subcutaneous administration of adamts13
GB201410693D0 (en) 2014-06-16 2014-07-30 Univ Southampton Splicing modulation
AU2015327836B2 (en) 2014-10-03 2021-07-01 Cold Spring Harbor Laboratory Targeted augmentation of nuclear gene output
CN105991563B (zh) * 2015-02-05 2020-07-03 阿里巴巴集团控股有限公司 一种保护敏感数据安全的方法、装置及三方服务系统
WO2016186994A1 (en) * 2015-05-15 2016-11-24 Children's Medical Center Corporation Methods relating to the diagnosis and treatment of thrombotic microangiopathy
CN108603230A (zh) 2015-10-09 2018-09-28 南安普敦大学 基因表达的调节与蛋白质表达失调的筛选
WO2017106377A1 (en) 2015-12-14 2017-06-22 Cold Spring Harbor Laboratory Antisense oligomers for treatment of autosomal dominant mental retardation-5 and dravet syndrome
US11096956B2 (en) 2015-12-14 2021-08-24 Stoke Therapeutics, Inc. Antisense oligomers and uses thereof
ES2983978T3 (es) 2016-01-08 2024-10-28 Univ Kyoto Medicina que comprende ADAMTS13 como ingrediente principal
IL264372B2 (en) * 2016-08-04 2024-05-01 Baxalta Inc Adamts13 for use in treating, ameliorating and/or preventing vaso-occlusive crisis in sickle cell disease
KR102318434B1 (ko) 2017-08-25 2021-11-01 스톡 테라퓨틱스, 인크. 병태 및 질환 치료용 안티센스 올리고머
CA3099280A1 (en) 2018-05-04 2019-11-07 Stoke Therapeutics, Inc. Methods and compositions for treatment of cholesteryl ester storage disease
AU2020227825B2 (en) 2019-02-27 2026-03-26 Stoke Therapeutics, Inc. Antisense oligomers for treatment of conditions and diseases
WO2021067668A1 (en) * 2019-10-04 2021-04-08 The Children's Medical Center Corporation Adamts13 treatment to enhance graft survival
US20230203469A1 (en) 2020-04-02 2023-06-29 Takeda Pharmaceutical Company Limited Adamts13 variant, compositions, and uses thereof
CN115867657A (zh) 2020-05-11 2023-03-28 斯托克制药公司 用于治疗疾患和疾病的opa1反义寡聚物
CN115835904A (zh) 2020-05-22 2023-03-21 武田药品工业有限公司 用于治疗和诊断冠状病毒疾病并发症的adamts13组合物和方法
US20230405096A1 (en) * 2020-11-18 2023-12-21 Green Cross Corporation Adamts13 variant having increased escaping rate or activity against autoantibody
WO2024151093A1 (ko) * 2023-01-11 2024-07-18 주식회사 녹십자 혈전성 질환의 예방 또는 치료를 위한 신규한 액상 제형물

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5082218A (de) * 1973-11-10 1975-07-03
US4791138A (en) * 1983-12-14 1988-12-13 The Upjohn Company Method for treating or preventing deep vein thrombosis using lipoxygenase inhibitors
US7754855B1 (en) * 1999-07-13 2010-07-13 Bolder Biotechnology, Inc. Immunoglobulin fusion proteins
US6926894B2 (en) * 2000-11-22 2005-08-09 Baxter Aktiengesellschaft Composition exhibiting a von willebrand factor (vWF) protease activity comprising a polypeptide chain with the amino acid sequence AAGGILHLELLV
JP2003284570A (ja) 2001-04-25 2003-10-07 Chemo Sero Therapeut Res Inst フォンビルブラント因子（ｖＷＦ）切断酵素
AU2002336367A1 (en) * 2001-08-16 2003-03-03 The Regents Of The University Of Michigan Adamts13 genes and proteins and variants, and uses thereof
US20030073115A1 (en) * 2002-09-16 2003-04-17 Shyam Ramakrishnan Regulation of human galanin receptor-like g protein coupled receptor
US7763430B2 (en) * 2003-04-22 2010-07-27 Baxter International Inc. Diagnostic assay for anti-von Willebrand Factor cleaving protease (ADAMTS13) antibodies
EP1568782A1 (de) * 2004-02-25 2005-08-31 Clemens Bockmeyer Diagnose und Therapie von ADAMTS-13 assoziierten Erkrankungen
ATE544866T1 (de) 2005-06-17 2012-02-15 Baxter Int Adamts13-haltige zusammensetzungen mit thrombolytischer wirkung

Also Published As

Publication number Publication date
US20220002703A1 (en) 2022-01-06
CA2606351C (en) 2016-12-13
CA2606351A1 (en) 2006-12-21
AU2006257073A1 (en) 2006-12-21
US10233436B2 (en) 2019-03-19
US11124787B2 (en) 2021-09-21
AU2006257073B2 (en) 2011-08-04
WO2006133955A8 (en) 2007-11-29
DK1902141T3 (da) 2012-05-07
US20130136732A1 (en) 2013-05-30
EP1902141A1 (de) 2008-03-26
HK1118579A1 (en) 2009-02-13
ES2382104T3 (es) 2012-06-05
EP1902141B1 (de) 2012-02-08
WO2006133955A1 (en) 2006-12-21
US20070015703A1 (en) 2007-01-18
US20190161746A1 (en) 2019-05-30
PL1902141T3 (pl) 2012-12-31

Similar Documents

Publication Publication Date Title
ATE544866T1 (de) Adamts13-haltige zusammensetzungen mit thrombolytischer wirkung
MY155961A (en) Chemical compounds 251
MX2009000285A (es) Piperidinas sustituidas que incrementan la actividad de p53 y usos de las mismas.
EA200870019A1 (ru) Лактамовые соединения и способы их применения
EP2493507A4 (de) Ax213- und ax132-pcsk9-antagonisten und varianten davon
EA201300242A1 (ru) Фармацевтические композиции, содержащие замещенные ациланилиды
TW200602048A (en) Diphenylimidazopyrimidine and -imidazole amines as inhibitors of β -secretase
EA200601776A1 (ru) Метадоновые композиции местного действия и способы их применения
ATE433973T1 (de) Azolylaminoazine als inhibitoren von proteinkinasen
TW200745124A (en) Azepinoindole derivatives as pharmaceutical agents
MX2012004551A (es) Nuevas composiciones para prevenir y/o tratar trastornos de almacenamiento lisosomal.
SG165315A1 (en) Alpha2c adrenoreceptor agonists
WO2008148074A3 (en) Inhibitors of mtor and methods of treatment using same
ATE322265T1 (de) Pharmazeutische zusammensetzung zur behandlung von kolorektalem krebs welche thalidomid und irinotecan enthält
MY143795A (en) Tetrahydropyridoindole derivatives
CY1109191T1 (el) Μια νεα χρηση της δεφεριπρονης
NO20076405L (no) Anvendelse av 24-nor-UDCA
ATE538799T1 (de) Zusammensetzungen zur behandlung von haarverlust
UA91848C2 (ru) Применение соединений диосметина в лечении и предотвращении тромботическим патологиям
TW200716204A (en) Pharmaceutical composition
TW200716091A (en) New therapeutic combinations for the treatment or prevention of psychotic disorders
ATE435858T1 (de) Prodrugs von als erk-proteinkinase-inhibitoren wirkenden pyrrolylpyrimidinen
WO2007041614A3 (en) Long acting vegf inhibitors and methods of use
BR0111785A (pt) Composições e métodos para tratamento de candidìase
MXPA06007007A (es) Derivados de prolina usados como ingredientes farmaceuticos activos para el tratamiento de tumores.